Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Vitamin D receptor agonists (VDRAs) inhibit the renin-angiotensin system (RAS) and reduce podocyte loss and fibrosis over and above RAS blockade. Several studies in humans show that VDRAs are antiproteinuric and have the potential to delay the progression of renal disease. Whether VDRAs will accomplish this goal among proteinuric patients with chronic kidney disease needs to be tested in randomized controlled trials.

Original languageEnglish
Pages (from-to)943-945
Number of pages3
JournalKidney International
Volume77
Issue number11
DOIs
StatePublished - 2010

Fingerprint

Calcitriol Receptors
Angiotensin-Converting Enzyme Inhibitors
Renin-Angiotensin System
Podocytes
Chronic Renal Insufficiency
Disease Progression
Fibrosis
Randomized Controlled Trials
Kidney

ASJC Scopus subject areas

  • Nephrology

Cite this

Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects. / Agarwal, Rajiv.

In: Kidney International, Vol. 77, No. 11, 2010, p. 943-945.

Research output: Contribution to journalArticle

@article{febf6b49fffc40588b2f8a611bdee6d3,
title = "Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects",
abstract = "Vitamin D receptor agonists (VDRAs) inhibit the renin-angiotensin system (RAS) and reduce podocyte loss and fibrosis over and above RAS blockade. Several studies in humans show that VDRAs are antiproteinuric and have the potential to delay the progression of renal disease. Whether VDRAs will accomplish this goal among proteinuric patients with chronic kidney disease needs to be tested in randomized controlled trials.",
author = "Rajiv Agarwal",
year = "2010",
doi = "10.1038/ki.2010.77",
language = "English",
volume = "77",
pages = "943--945",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects

AU - Agarwal, Rajiv

PY - 2010

Y1 - 2010

N2 - Vitamin D receptor agonists (VDRAs) inhibit the renin-angiotensin system (RAS) and reduce podocyte loss and fibrosis over and above RAS blockade. Several studies in humans show that VDRAs are antiproteinuric and have the potential to delay the progression of renal disease. Whether VDRAs will accomplish this goal among proteinuric patients with chronic kidney disease needs to be tested in randomized controlled trials.

AB - Vitamin D receptor agonists (VDRAs) inhibit the renin-angiotensin system (RAS) and reduce podocyte loss and fibrosis over and above RAS blockade. Several studies in humans show that VDRAs are antiproteinuric and have the potential to delay the progression of renal disease. Whether VDRAs will accomplish this goal among proteinuric patients with chronic kidney disease needs to be tested in randomized controlled trials.

UR - http://www.scopus.com/inward/record.url?scp=77955881910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955881910&partnerID=8YFLogxK

U2 - 10.1038/ki.2010.77

DO - 10.1038/ki.2010.77

M3 - Article

C2 - 20467430

AN - SCOPUS:77955881910

VL - 77

SP - 943

EP - 945

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 11

ER -